297 related articles for article (PubMed ID: 15301561)
1. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease.
Han PD; Cohen RD
Drugs; 2004; 64(16):1767-77. PubMed ID: 15301561
[TBL] [Abstract][Full Text] [Related]
2. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
Sandborn WJ; Hanauer SB
Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
[TBL] [Abstract][Full Text] [Related]
6. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort.
Teshima CW; Thompson A; Dhanoa L; Dieleman LA; Fedorak RN
Can J Gastroenterol; 2009 May; 23(5):348-52. PubMed ID: 19440565
[TBL] [Abstract][Full Text] [Related]
7. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
8. How to improve the safety of biologic therapy in Crohn's disease.
Ferkolj I
J Physiol Pharmacol; 2009 Dec; 60 Suppl 7():67-70. PubMed ID: 20388947
[TBL] [Abstract][Full Text] [Related]
9. Long term safety of infliximab.
Schaible TF
Can J Gastroenterol; 2000 Sep; 14 Suppl C():29C-32C. PubMed ID: 11023558
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics and use of infliximab.
Klotz U; Teml A; Schwab M
Clin Pharmacokinet; 2007; 46(8):645-60. PubMed ID: 17655372
[TBL] [Abstract][Full Text] [Related]
11. Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.
Kiss LS; Lovasz BD; Golovics PA; Vegh Z; Farkas K; Molnar T; Palatka K; Papp M; Mohas A; Szilagyi BK; Fekete SA; Mandel M; Lakatos PL
J Gastrointestin Liver Dis; 2013 Jun; 22(2):135-40. PubMed ID: 23799211
[TBL] [Abstract][Full Text] [Related]
12. [A case of psoriasis induced by infliximab treatment for Crohn's disease].
Jwa YJ; Kim NH; Park HJ; Park JS; Bae WK; Kim KA; Lee JS; Moon YS
Korean J Gastroenterol; 2010 Nov; 56(5):324-8. PubMed ID: 21099241
[TBL] [Abstract][Full Text] [Related]
13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of inflammatory diseases: safety of long-term use of infliximab].
Schaible TF
Presse Med; 2001 Mar; 30(12):610-3. PubMed ID: 11317923
[TBL] [Abstract][Full Text] [Related]
15. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease.
Sandborn WJ
Rev Gastroenterol Disord; 2004; 4 Suppl 3():S25-33. PubMed ID: 15583528
[TBL] [Abstract][Full Text] [Related]
16. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.
Vermeire S; Noman M; Van Assche G; Baert F; Van Steen K; Esters N; Joossens S; Bossuyt X; Rutgeerts P
Gastroenterology; 2003 Jul; 125(1):32-9. PubMed ID: 12851868
[TBL] [Abstract][Full Text] [Related]
17. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
18. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease.
Seddik M; Meliez H; Seguy D; Viget N; Cortot A; Colombel JF
Inflamm Bowel Dis; 2004 Jul; 10(4):436-7. PubMed ID: 15475754
[TBL] [Abstract][Full Text] [Related]
20. Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab.
Reumaux D; Bardin N; Colombel JF; Dignat-George F; Duthilleul P; Vermeire S
Inflamm Bowel Dis; 2007 Oct; 13(10):1315-7. PubMed ID: 17476677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
